Subscribe or Manage Preferences

Value in Oncology

An international collaborative pilot study found large differences by country in retail prices for 23 cancer drugs, with the highest retail prices in the United States and the lowest in India and South Africa.
The first oncology biosimilar—filgrastim-sndz (Zarxio)—was approved in the United States in March 2015, but this category of drugs is still fairly misunderstood, according to Jim M. Koeller, MS, Professor, College of Pharmacy, University of Texas at Austin.
Women with clinicopathologic high-risk breast cancer had nearly a 50% reduction in prescription chemotherapy, with no increased risk for metastatic recurrence when a cancer gene-based assay was used to guide treatment decision-­making, according to new data presented at the 2016 American Association for Cancer Research meeting.
Patients with cancer increasingly wish to discuss costs with their oncologists, whose knowledge of treatment costs is limited. At the 2016 ASCO Quality Care Symposium, Nora B. Henrikson, PhD, MPH, of Group Health Research Institute, Seattle, WA, presented the results from a pilot project called OPT-IN, which aims at increasing clinician access to treatment prices in the clinical setting.
A study using the FDA Adverse Event Reporting System (FAERS) has demonstrated the high cost burden of adverse events (AEs) associated with the use of tyrosine kinase inhibitors (TKIs) in patients with chronic myelogenous leukemia (CML). The results were presented at ASH 2015 by Nicola Wallis, MRCPath, FFPM, Bristol-Myers Squibb, Princeton, NJ.
Surgery for the primary treatment of T1-T3 oropharynx squamous-­cell carcinoma (OPC) does not increase the cost of care, even for patients requiring adjuvant treatment, according to A. Daniel Pinheiro, MD, an otolaryngologist at Mercy Clinic Ear, Nose, and Throat-Surgery Center, Springfield, MO, who presented his findings at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
On January 16, 2016, President Barack Obama promised a “moonshot” to accelerate national progress to combat cancer, but delivering on that promise faces many challenges.
A study of state-specific costs of care and survival among Medicare beneficiaries with myelodysplastic syndromes (MDS) shows no correlation between the cost of care and patient outcomes.
The use of cost data to inform infrastructure investments can help cancer centers move toward value-based payment models, improve end-of-life planning, and reduce futile care, according to Kerin B. Adelson, MD, Chief Quality Officer and Deputy Chief Medical Officer, Smilow Cancer Hospital (SCH) at Yale-New Haven, CT.
Researchers in Chicago have developed a financial toxicity grading system based on clinically meaningful changes in health-related quality of life. According to lead investigator Jonas A. de Souza, MD, Assistant Professor of Medicine, University of Chicago, at the 2016 Cancer Survivorship Symposium, the tool has been validated in 2 separate cohorts of patients with cancer, with plans for a larger, prospective study underway.
Page 1 of 4
Results 1 - 10 of 32
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology